| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-11-07 | Spinraza™ (nusinersen - ISIS-SMNRx - antisense oligonucleotide targeted to the SMN2 gene) | spinal muscular atrophy | 3 | Isis Pharmaceuticals (USA - CA), now Ionis Pharmaceuticals (USA - CA) | Neuromuscular diseases - Rare diseases - Genetic diseases |
| 2016-11-07 | SynGEM® | Respiratory Syncytial Virus (RSV) infection | 1 | Mucosis (The Netherlands) | Infectious diseases |
| 2016-11-07 | CK?2018571 (CK-571) | preclinical | Cytokinetics (USA - CA) | Lung diseases - Respiratory diseases | |
| 2016-11-04 | Livatag® (doxorubicin Transdrug®) | pancreatic cancer | preclinical | Onxeo (France) | Cancer - Oncology |
| 2016-11-03 | emricasan | NASH (non-alcoholic steatohepatitis) | 2 | Conatus Pharmaceuticals (USA - CA) | Hepatic diseases - Liver diseases |
| 2016-11-03 | AGS-003 | metastatic renal cell carcinoma (mRCC) | 2 | Argos Therapeutics (USA - NC) | Cancer - Oncology |
| 2016-11-03 | BL-8040 | acute myeloid leukemia (AML) | 2a | BioLineRx (Israel) | Cancer - Oncology |
| 2016-11-02 | BP1001 (liposomal Grb2 antisense oligonucleotide) | acute myeloid leukemia (AML) | 2 | Bio-Path Holdings (USA - TX) | Cancer - Oncology |
| 2016-11-02 | M834 | 1 | Mylan (USA - PA) Momenta Pharmaceuticals (USA - MA) | ||
| 2016-11-02 | baricitinib (LY3009104) | rheumatoid arthritis | 3 | Eli Lilly (USA - IN) Incyte Corporation (USA - DE) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2016-11-02 | glesatinib, sitravatinib or mocetinostat in combination with nivolumab | non-small cell lung cancer (NSCLC) | 2 | Mirati Therapeutics (USA - CA) | Cancer - Oncology |
| 2016-11-01 | NVP018 | NASH (non-alcoholic steatohepatitis) | preclinical | Neurovive Pharmaceutical (Sweden) | Liver diseases - Hepatic diseases |
| 2016-11-01 | bococizumab | hyperlipidemia | 3 | Pfizer (USA - NY) | Cardiovascular diseases - Metabolic diseases |
| 2016-11-01 | IONIS-FXIRx | patients with end-stage renal disease (ESRD) on hemodialysis | 2 | Ionis Pharmaceuticals (USA - CA) | Renal diseases - Kidney diseases |
| 2016-10-31 | E2609 | Alzheimer's disease | 3 | Eisai (Japan) | Neurodegenerative diseases |
| 2016-10-31 | telotristat etiprate | carcinoid syndrome patients with metastatic neuroendocrine tumor (NET) inadequately controlled by somatostatin analog (SSAs) | 3 | Ipsen (France) Lexicon Pharmaceuticals (USA - TX) | Cancer - Oncology |
| 2016-10-28 | Tcelna (imilecleucel-T) | secondary progressive multiple sclerosis | 2 | Opexa Therapeutics (USA - TX) | Autoimmune diseases - Neurodegenerative diseases |
| 2016-10-28 | lemborexant (E2006) | patients with Irregular Sleep-Wake Rhythm Disorder and mild to moderate Alzheimer’s disease dementia | 2 | Eisai (Japan) | Neurodegenerative diseases - Neurological diseases |
| 2016-10-27 | Beleodaq™ (belinostat) and immune checkpoint inhitors | preclinical | Onxeo (France) | Cancer - Oncology | |
| 2016-10-27 | HinsBet® U100 | type 1 diabetes | 1-2a | Adocia (France) | Metabolic diseases |
